


**SPECIFICATIONS**

|                         |  |
|-------------------------|--|
| <b>Catalog Number</b>   | C3015  |
| <b>Cell Line Name</b>   | Human PSGL-1-CHO-K1 stable cell line (HuPSGL-1-CHO-K1) |
| <b>Accession Number</b> | #AAC50061  |
| <b>Host Cell</b>        | Adherent CHO-K1  |
| <b>Quantity</b>         | Two vials of frozen cells (2x10 <sup>6</sup> per vial) |
| <b>Culture Medium</b>   | DMEM with 10% FBS, 4µg/ml puromycin                    |
| <b>Freezing Medium</b>  | 90% FBS and 10% DMSO                                   |
| <b>Storage</b>          | Liquid nitrogen  |

**DATA**

Detection of human PSGL-1 expression on human PSGL-1-CHO-K1 stable cells using a monoclonal antibody specific for human PSGL-1 (BioLegend, Cat #328805)


**BACKGROUND**

Human PSGL-1, also known as P-selectin glycoprotein ligand-1, is a glycoprotein expressed on the surface of white blood cells. It is primarily known for its role in the immune system, specifically in the process of leukocyte rolling and recruitment during inflammation. PSGL-1 functions as a binding site for selectin family proteins, such as P-selectin, E-selectin, and L-selectin, which are expressed on the surface of endothelial cells and platelets. This interaction between selectins and PSGL-1 enables the initial tethering and rolling of leukocytes along the vessel wall, which is a crucial step in the process of inflammation and immune response. PSGL-1 can be found on the surfaces of leukocytes, including neutrophils, monocytes, and T-lymphocytes. Another role for PSGL-1 in the immune system is its negative regulatory function of T cells serving as a checkpoint in immune responses. Studies have suggested that PSGL-1 may play a role in cancer progression and metastasis since high levels of PSGL-1 expression have been linked to increased angiogenesis, tumor invasion, and metastasis. As a result of its involvement in immune response and cancer progression, PSGL-1 has emerged as a potential therapeutic target for various diseases. Several drugs targeting PSGL-1 have been developed and are currently being studied in preclinical and clinical trials.

**References**

- Carlow DA, Gossens K, Naus S, Veerman KM, Seo W, Ziltener HJ. PSGL-1 function in immunity and steady state homeostasis. *Immunol Rev.* **230(1)**:75-96. 2009.
- DeRogatis JM, Viramontes KM, Neubert EN, Tinoco R. PSGL-1 Immune Checkpoint Inhibition for CD4<sup>+</sup> T Cell Cancer Immunotherapy. *Front Immunol.* **12**:636238. 2021.
- Tinoco R, Otero DC, Takahashi AA, Bradley LM. PSGL-1: A New Player in the Immune Checkpoint Landscape. *Trends Immunol.* **38(5)**:323-335. 2017.

*Disclaimer: For research use only. Not for use in humans.*